Comparing two chemotherapies after breast cancer surgery
Part of Cancer, Skin clinical trials.
This trial is comparing two types of chemotherapy (standard taxane vs a newer albumin-bound paclitaxel) given after surgery to see which is better at preventing breast cancer from returning. It is for women with HER2-negative breast cancer that has a high risk of coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female and between 18 and 70 years old.
- You have been diagnosed with invasive breast cancer that is HER2-negative (a type that doesn't have too much HER2 protein).
- You have already had surgery to remove the tumor (like a mastectomy or lumpectomy) and the margins (edges) were clear of cancer.
- Your doctor plans to give you a specific chemotherapy regimen (called AC-T) after surgery.
- You have a high risk of the cancer coming back (for example, it spread to lymph nodes or had aggressive features).
- You have not had any prior treatment for breast cancer (other than surgery).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial compares nab-PH plus pyrrolitinib versus TCbHP as treatment given before breast surgery. It aims to see which option works better and is safe for people with HER2-positive invasive breast cancer.
This trial compares two different chemotherapy combinations given before surgery (neoadjuvant therapy) for people with triple-negative breast cancer. It looks to see which drug combination works better to control the cancer before and around the time of the operation.
This trial tests whether giving chemotherapy before surgery, guided by the genetic profile of your tumor, can improve outcomes for a specific type of HER2-positive breast cancer. It aims to tailor treatment to each person's cancer biology.
This phase 3 trial compares two pre-surgery treatment plans for people with HER2-positive invasive breast cancer that has spread to nearby lymph nodes. It aims to see which plan works better to shrink the tumor before surgery and improve outcomes.
This Phase 4 study tests an additional (adjuvant) treatment for breast cancer after surgery and standard follow-up care. It may help lower the chance the cancer comes back, but you must match specific tumor and body-chemistry requirements to join.
This trial tests two different combinations of chemotherapy and targeted therapy given before surgery for HER2-positive breast cancer. The goal is to see which combination works better at shrinking the tumor.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.